Keyphrases
Single Center
100%
Acute Myeloid Leukemia
100%
Retrospective Review
100%
FMS-like Tyrosine Kinase 3 (FLT3)
100%
Clinical Outcomes
100%
Induction Chemotherapy
63%
Hypomethylating Agents
54%
Complete Response
54%
Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT)
45%
Relapse-free Survival
45%
Cytarabine
36%
Fludarabine
36%
Idarubicin
36%
Venetoclax
27%
Internal Tandem Duplication
27%
Leukemia Patients
18%
Point mutation
18%
Overall Response Rate
18%
Duplication mutation
18%
Day Range
18%
Maintenance Therapy
9%
Targeted Therapy
9%
Hispanic
9%
Measurement Analysis
9%
Older Patients
9%
Remission
9%
FLT3 mutation
9%
Duration of Response
9%
Relapse Risk
9%
People of Color
9%
Gilteritinib
9%
Highly Effective
9%
March 2013
9%
All-trans Retinoic Acid
9%
Activating mutation
9%
Normal Karyotype
9%
Induction Mortality
9%
Nucleophosmin 1 (NPM1)
9%
Adverse Risk
9%
Tyrosine Kinase Domain
9%
Tyrosine Kinase Domain mutations
9%
De Novo Acute Myeloid Leukemia
9%
Intervention Fit
9%
Arsenic Trioxide
9%
IA-2
9%
Unfit Patients
9%
White People
9%
DNMT3A mutation
9%
Medicine and Dentistry
Acute Myeloid Leukemia
100%
CD135 Antigen
100%
Induction Chemotherapy
63%
Hypomethylating Agent
54%
Allogeneic Stem Cell Transplantation
45%
Recurrence Free Survival
45%
Cytarabine
36%
Fludarabine
36%
Idarubicin
36%
Venetoclax
27%
Protein Tyrosine Kinase
18%
Point Mutation
18%
Targeted Therapy
9%
De Novo Acute Myeloid Leukemia
9%
Maintenance Therapy
9%
Gilteritinib
9%
Tretinoin
9%
Arsenic Trioxide
9%
NPM1
9%
DNA Methyltransferase 3A
9%
Karyotype
9%
Biochemistry, Genetics and Molecular Biology
Tyrosine Kinase
100%
Myeloid
100%
Receptor Tyrosine Kinase
100%
Allogeneic Stem Cell Transplantation
41%
Recurrence Free Survival
41%
Fludarabine
33%
Idarubicin
33%
Cytarabine
33%
Point Mutation
16%
Karyotype
8%
DNMT3A
8%
NPM1
8%
Tretinoin
8%
Arsenite
8%
Arsenic Trioxide
8%
Arsenous Acid
8%
Targeted Therapy
8%
Pharmacology, Toxicology and Pharmaceutical Science
CD135 Antigen
100%
Acute Myeloid Leukemia
100%
Chemotherapy
63%
Recurrence Free Survival
45%
Idarubicin
36%
Cytarabine
36%
Fludarabine
36%
Venetoclax
27%
Protein Tyrosine Kinase
18%
Arsenite
9%
Remission
9%
Retinoic Acid
9%
Gilteritinib
9%
De Novo Acute Myeloid Leukemia
9%
DNA Methyltransferase 3A
9%
Arsenous Acid
9%